Public and Patients
- About Us
- Cancer Information
- Clinical Trials
- Events & Outreach
- Make a Gift
- News & Feature Stories
- Survivorship
Researchers and Staff
Cancer Center Update
December 13, 2005
Cancer Center Update is sent to Cancer Center members and staff every Tuesday at 10 a.m. To submit an item for publication, send the information to Sandi Sherman by noon the Friday before publication.
In This Issue:
Professional Education and Seminars
Grant Information & Announcements
There is no seminar scheduled for Tuesday, December 13, due to the ASH meeting
A peek at next week’s seminar:
Regulation of breast cell differentiation and gene expression by mechanical signaling from collagen matrices
Patricia J. Keely, Ph.D., Assistant Professor, Department of Pharmacology, University of Wisconsin-Madison
Host: Yoji Shimizu, Ph.D.
For a complete schedule visit: http://www.cancer.umn.edu/page/aboutus/date.html
ATTENTION ASH PARTICIPANTS
In next week’s Update we would like to list the Masonic Cancer Center members who presented oral and poster presentations at the annual ASH meeting in Atlanta. If you presented, please forward your name, academic title, title of the presentation, and type of presentation (oral, poster, moderator) to Sandi Sherman at sherm019@umn.edu.
.
DECEMBER 19 DEADLINE FOR DAMON RUNYON CANCER RESEARCH FOUNDATION SCHOLAR AWARD NOMINATIONS
The Damon Runyon Cancer Research Foundation is offering Scholar Awards to support the development of outstanding scientists as they establish their own independent research laboratories. Assistant Professors in the first three years of their appointment who do not have another career development award are eligible to apply. The applicant's scientific accomplishments must show promise of future contributions that will lead to understanding the causes and mechanisms of cancer and to developing more effective cancer therapies and preventions. This is a three-year award for $100,000 per year. A total of five projects will be awarded.
Two nominations are permitted per institution (one basic scientist and one physician-scientist [MD or MD/PhD affiliated with a clinical department]), plus an unlimited number of applications by former Damon Runyon Fellows. Potential applicants should submit a preliminary proposal of 1-2 pages in length plus a curriculum vitae. If there are multiple applicants/nominations, a sub committee of the Masonic Cancer Center 's Executive Committee will screen applications/nominations and select the 2 finalists. Nominating materials should be sent via e-mail to Mary Sumpmann (sumpm001@umn.edu) before December 19th, 2005.
Questions should be addressed to Mark Paller, Assistant Vice President for Research, AHC (palle001@umn.edu). For more information visit the Damon Runyon Cancer Research Fund web site at www.drcrf.org/apScholar.html.
DEPARTMENT OF PEDIATRICS AND CANCER CENTER CLINICAL TRIALS OFFICE ANNOUNCES PROGRAM DIRECTOR' S RETIREMENT
Bonnie Sweeney, Program Director of the Clinical Trials Office of the Department of Pediatrics and the Masonic Cancer Center, is retiring from the University of Minnesota as of December 27, 2005. Bonnie has been with the Clinical Trials Office for nearly four years and with the University for over 20 years. She has played a crucial role in the development of the organization and has been key to the success of our clinical and translational research programs. Over the next few weeks, the Clinical Trials Office will begin the process of recruiting an individual to fill this vacancy.
FUNDING NOTICE FROM THE NIH
(http://www.nih.gov)
The Department of Health and Human Services (HHS) continues to operate on a continuing resolution (CR) that currently extends through December 17, 2005 . The CR applies the terms of the FY 2005 appropriations for the period covered by the CR. Until the final FY 2006 appropriation is enacted, NIH will be issuing non-competing research grant awards at a level below that indicated on the most recent Notice of Award (generally up to 80% of the previously committed level). NIH will consider upward adjustments to these levels after the final appropriation is enacted, but expects institutions to monitor their expenditures carefully during this period. Questions regarding adjustments applied on individual grant awards may be directed to the Grants Management Specialist identified on the Notice of Award.
NOTICE OF AVAILABILITY OF ADMINISTRATIVE SUPPLEMENTS FOR ACTIVITIES TO PROMOTE RESEARCH COLLABORATIONS FOR PROJECTS CURRENTLY FUNDED BY THE NCI DIVISION OF CANCER BIOLOGY
The Division of Cancer Biology (DCB) of the National Cancer Institute (NCI) invites requests for supplemental funding in fiscal year 2006 for existing DCB-funded research projects (i.e., administrative supplements) to support and encourage new multidisciplinary scientific collaborations among DCB grantees, as well as with other members of the scientific community. This initiative, known as the Activities to Promote Research Collaborations (APRC), supports collaborative interdisciplinary activities that bring together ideas and approaches from disparate scientific disciplines including those not currently supported by DCB.
To read the entire notice and for further information see
http://grants.nih.gov/grants/guide/notice-files/NOT-CA-06-003.html
MENTORED QUANTITATIVE RESEARCH DEVELOPMENT AWARD (K25)
NIH
The K25 Award will support the career development of quantitatively trained investigators who make a commitment to basic or clinical biomedicine, bioengineering, bioimaging or behavioral research that is relevant to the NIH mission. This award provides support for a period of supervised study and research for productive professionals with quantitative backgrounds who have the potential to integrate their quantitative expertise with NIH-relevant research and develop into productive investigators. The K25 program is intended for research-oriented investigators from the postdoctoral level to the level of senior faculty.
To read the entire program announcement and for further information see
http://grants.nih.gov/grants/guide/pa-files/PA-06-087.html#PartII
INNOVATIVE TECHNOLOGIES FOR MOLECULAR ANALYSIS OF CANCER (R21, R33)
NCI/NIH
Application Receipt Date(s): February 22, 2006; May 26, 2006
The National Cancer Institute (NCI) invites applications for research projects proposing the development of highly innovative cancer relevant molecular technologies. Technology encompasses methods and tools that enable research, including, but not limited to, instrumentation, techniques, and devices. Molecular technologies are distinct from resources such as databases, individual reagents, therapeutic agents, and tissue repositories, and do not include the development of whole body imaging technologies. Repositories, agent development, whole body imaging technologies, and software development are supported through other initiatives. This Request for Applications (RFA) will use the NIH R21 Exploratory/Developmental and the R33 Exploratory/Developmental Phase 2 award mechanisms.
To read the entire notice and for further information see
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-07-001.html
APPLICATION OF EMERGING TECHNOLOGIES FOR CANCER RESEARCH (R21, R21/R33)
NCI/NIH
Application Receipt Date(s): February 22, 2006; May 26, 2006
The National Cancer Institute (NCI) invites applications for research projects to evaluate the usefulness of emerging molecular technologies that are ready for initial application to clinical or biological questions in cancer research. Technology encompasses methods and tools that enable research, including, but not limited to, instrumentation, techniques, and devices. Molecular technologies are distinct from resources such as databases, individual reagents, therapeutic agents, and tissue repositories, and do not include the development of whole body imaging technologies. Repositories, agent development, whole body imaging technologies, and software development are supported through other initiatives. This funding opportunity will use the NIH R21 Exploratory/Developmental award, R21/R33 Phased Innovation award, and the R33 Exploratory/Developmental Phase 2 award mechanisms.
To read the entire notice and for further information see
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-07-002.html
INNOVATIONS IN CANCER SAMPLE PREPARATION (R21, R33, R21/R33)
NCI/NIH
Application Receipt Date(s): February 22, 2006; May 26, 2006
The National Cancer Institute (NCI) invites applications for research projects involving the development and significant enhancement or adaptation of sample preparation methodologies and technologies, the development of assays to assess sample quality, and studies designed to elucidate the criteria by which to judge sample quality. The outcome will be products and methods designed to optimize sample utility. This RFA will use NIH Exploratory/Developmental Research Grant (R21), Exploratory/Developmental Research Grant Phase 2 (R33), and the Phased Innovation Award (R21/R33) mechanisms.
To read the entire notice and for further information see
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-07-003.html
ADVANCED PROTEOMIC PLATFORMS AND COMPUTATIONAL SCIENCES FOR THE NCI CLINICAL PROTEOMIC TECHNOLOGIES INITIATIVE (R01, R21, R21/R33)
NCI/NIH
Application Receipt Date(s): April 11, 2006
The National Cancer Institute (NCI) invites applications for research project grants to support highly innovative research in the quantitative analysis of proteins and peptides of interest in clinical cancer studies. This funding opportunity is a component of the NCI’s Clinical Proteomic Technologies Initiative for Cancer (http://proteomics.cancer.gov) that aims to improve the technological capability to reliably identify, quantify, and compare measurements and analyses of proteins and peptides in complex biological mixtures. This funding opportunity involves the use of the NIH R01, R21, and combined R21/R33 grant mechanisms.
To read the entire notice and for further information see
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-07-005.html
PFIZER, INC. 2006 VISITING PROFESSORSHIP IN ONCOLOGY
Application deadline: January 27, 2006
This program is designed to advance oncology by creating opportunities for educational visits by prominent cancer experts to U.S. medical schools/teaching hospitals and cancer centers. These unrestricted educational grants are nationally competitive, and grant recipients are chosen by an independent Academic Advisory Board of recognized leaders in oncology.
Up to ten grants of $7,500 each will be awarded to selected organizations ("Host Institutions") to cover the Visiting Professors' honorarium, travel expenses, and other direct expenses related to the visit. A visit may occur between June 2006 and June 2007. The purpose of the visit is to bring new educational value to the institution; therefore, it should not be part of or adjunct to a previously planned or regularly scheduled program/event.
For further information see
http://www.promisingminds.com/GrantsProgType.aspx?ProgID=308&ProgTypeID=1
DORIS DUKE CLINICAL SCIENTIST DEVELOPMENT AWARD
Deadline: Pre-Proposals: January 31, 2006; Invited Proposals: April 18, 2006
The Doris Duke Clinical Scientist Development Award provides grants to junior physician-scientists to facilitate their transition to independent clinical research careers. In 2006, up to 12 three–year grants of $125,000 per year in direct costs and $10,000 per year in indirect costs will be awarded to junior physician-scientists conducting clinical research.
For further information see http://www.ddcf.org/page.asp?pageId=291.
DORIS DUKE DISTINGUISHED CLINICAL SCIENTIST AWARDS
Nomination packages: February 14, 2006
Invited proposals, June 6, 2006
The Doris Duke Charitable Foundation is sponsoring The Doris Duke Distinguished Clinical Scientist Award supports mid-career physician-scientists conducting “bench-to-bedside” (translational) research in any area of clinical investigation. This five-year award totals $1.5 million and is open to investigators at the associate professor level or higher who have an established translational clinical research program and an outstanding mentoring record.
The University may nominate up to two candidates. Nominations (by other faculty members) or preliminary proposals by applicants themselves should be 1-2 pages in length and describe why the nominee deserves the award and what research will be performed during the award period. A curriculum vitae should also be included. If there are multiple applicants/nominations, a committee of faculty members will select the finalist to represent the University. Questions should be addressed to Mark Paller, Assistant Vice President for Research, AHC (palle001@umn.edu). Nominating materials should be sent via email to Jen Trochinski (troc0021@umn.edu) before January 13, 2006. For additional information: http://ddcf.org/mrp-dcsa.
The Grant Opportunities web page is currently under construction. To view a list of cancer research funding resources and links to their web sites visit http://www.cancer.umn.edu/page/aboutus/grantopp.html .
CANCER PROGRESSION AND METASTASIS PROGRAM MEETING
Wednesday, December 14, 2005, 12:00-1:00 p.m., 450 CCRB
Multispectral high content cellular analysis using a flow-based imaging cytometer
Greg Veltri, Coordinator, Flow Cytometry Core Facility, Masonic Cancer Center
For a complete schedule visit http://www.cancer.umn.edu/page/aboutus/cellbiol.html .
CANCER EPIDEMIOLOGY INTEREST GROUP
Friday, December 16, 2005, 11:30 a.m.- 1:00 p.m., D-327 Mayo
Novel approaches to nicotine dependence
Dorothy Hatsukami, Ph.D., Forster Family Professor in Cancer Prevention, Professor, Department of Psychiatry, Director, Transdisciplinary Tobacco Use Research Center, University of Minnesota
Please RSVP to Logan Spector ( spector@epi.umn.edu ) by 4 pm on Tuesday, December 13th to reserve lunch.
For a complete schedule visit http://www.cancer.umn.edu/page/aboutus/epi_sem.html .
CORE CURRICULUM SEMINAR
Friday, December 16, 2005, 10:00 a.m., 450 CCRB
Head and neck malignancies
Patrick Gaffney, M.D., Assistant Professor, Department of Medicine
For a complete schedule visit http://www.cancer.umn.edu/page/aboutus/coreseminar.html
CANCER BIOLOGY RESEARCH CLUB
Friday, December 16, 2005, 3:30-4:30 p.m., 450 CCRB
Direct binding of endostatin to human ovarian cancer cells inhibits vessel cooption and peritoneal dissemination
Yumi Yokoyama, Ph.D., Ramakrishnan lab
For a complete schedule visit http://www.cancer.umn.edu/page/grant7.html .
BMT CONFERENCE
Monday, December 19, 2005, 1:15-2:15 p.m., 450 CCRB
Adult stem cells for tissue repair
Jakub Tolar, M.D., Ph.D., Assistant Professor. Pediatric Hematology/Oncology and Blood and Marrow Transplantation
For a complete schedule visit http://www.cancer.umn.edu/page/aboutus/bmtlect.html